Wan Yue

Wan Yue, Liu Xiangxiang, Yan Xuejing, Wu Shen, Teng Yufei, Han Luyi et al.

AAV-DJ-shMYOC gene therapy reduced mutant myocilin, preventing IOP elevation, preserving RGCs and visual function in young mice. It also lowered IOP in aged mice, showing potential for myocilin-related glaucoma by targeting the underlying proteinopathy.

Wan Yue, Guo Xinzheng, Wang Ningli

The trabecular meshwork's dysfunction is central to glaucoma's elevated eye pressure. New therapies, from drugs to gene and cell-based approaches, are targeting the TM to restore function and improve glaucoma treatment.

Han Luyi, Mao Yingyan, Sang Qing, Wan Yue, Wang Ningli

This study found microcatheter-assisted MIGS, specifically MAT, is as effective as trabeculectomy with MMC for IOP and medication reduction in open-angle glaucoma, with some MIGS offering complication advantages.

Wan Yue, Cao Kai, Wang Jin, Sun Yunxiao, Du Rong, Wang Ziyi et al.

GATT combined with cataract surgery effectively and safely lowered eye pressure and medication use for 24 months in patients with glaucoma and cataracts, offering a good treatment option.